



Newstar Medical Laboratories - Atlanta

975 Cobb Place Blvd NW, STE 218 Kennesaw, GA 30144

Phone: (678) 505-8016 | Fax:(678) 806-7192

CLIA ID: 11D2145553

Laboratory Director : Chesie Voma

PATIENT

DEMOGRAPHICS

| | | |
|--------------------------------------|--|--------------------------------------|
| Patient Name: MARY JONES | Account: Desert Kidney Associates Casa Grande Florence | Order Code: 2021-0011992 |
| DOB: 12/22/1951 | Provider: Ruchir Patel | Sample Type: Urine |
| Patient Gender: F | Accession: 21120600024 | Collected: 12/02/2021 |
| Patient Phone Number: (520) 868-4812 | Report Status: | Received: 2021-12-06T15:34:17.181050 |
| | | Reported: 04/05/2022 |

PRESCRIPTION

LIST

| | |
|--|---|
| Losartan (Cozaar) , Amlodipine (Norvasc) , Furosemide (Lasix) , Atorvastatin (Lipitor) , Oxycodone (OXY , Percocet , Endocet , Percodan , Percolone , Roxicodone , Tylox) , Vitamin D3 (cholecalciferol-D3) (D3-50) , Triamcinolone (Aristocort) , Zolpidem (Ambien) | C20, Z51.81, Z79.899, I10 Hypertension, N18.2 |
|--|---|

| INCONSISTENT | | | | INCONSISTENT | | |
|----------------|--|----------------|-----------------|--------------|--|----------------|
| NOT PRESCRIBED | | DETECTED | | PRESCRIBED | | NOT DETECTED |
| Class | Test | Cutoff (ng/mL) | Results (ng/mL) | Class | Test | Cutoff (ng/mL) |
| STIMULANT | Caffeine | 50 | > 2500 | STATIN | Atorvastatin | 10 |
| | [DDI] The metabolism of Zolpidem can be decreased when combined with Caffeine. [DDI] The metabolism of Zolpidem can be decreased when combined with Caffeine. [DDI] The metabolism of Zolpidem can be decreased when combined with Caffeine. [DDI] The metabolism of Zolpidem can be decreased when combined with Caffeine. [DDI] The metabolism of Zolpidem can be decreased when combined with Caffeine. [DDI] The metabolism of Zolpidem can be decreased when combined with Caffeine. [DDI] The metabolism of Zolpidem can be decreased when combined with Caffeine. | | | | [DDI] The metabolism of Atorvastatin can be decreased when combined with Losartan. [DDI] The metabolism of Atorvastatin can be decreased when combined with Losartan. [DDI] The metabolism of Atorvastatin can be decreased when combined with Losartan. [DDI] The metabolism of Atorvastatin can be decreased when combined with Losartan. [DDI] The metabolism of Atorvastatin can be decreased when combined with Losartan. [DDI] The metabolism of Atorvastatin can be decreased when combined with Losartan. [DDI] The metabolism of Atorvastatin can be decreased when combined with Losartan. [DDI] The metabolism of Oxycodone can be increased when combined with Triamcinolone. The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Furosemide. The metabolism of Zolpidem can be increased when combined with Triamcinolone. The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Atorvastatin. The metabolism of Amlodipine can be increased when combined with Triamcinolone. [DDI] The metabolism of Oxycodone can be increased when combined with Triamcinolone. The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Furosemide. The metabolism of Zolpidem can be increased when combined with Triamcinolone. The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Atorvastatin. The metabolism of Amlodipine can be increased when combined with Triamcinolone. [DDI] The metabolism of Oxycodone can be increased when combined with Triamcinolone. The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Furosemide. The metabolism of Zolpidem can be increased when combined with Triamcinolone. The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Atorvastatin. The metabolism of Amlodipine can be increased when combined with Triamcinolone. [DDI] The metabolism of Oxycodone can be increased when combined with Triamcinolone. The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Furosemide. The metabolism of Zolpidem can be increased when combined with Triamcinolone. The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Atorvastatin. The metabolism of Amlodipine can be increased when combined with Triamcinolone. [DDI] The metabolism of Oxycodone can be increased when combined with Triamcinolone. The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Furosemide. The metabolism of Zolpidem can be increased when combined with Triamcinolone. The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Atorvastatin. The metabolism of Amlodipine can be increased when combined with Triamcinolone. [DDI] The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Atorvastatin. | |

| CONTRAINDICATION | | NOT TESTED |
|------------------|--|------------|
| Drug | Contraindication | |
| Furosemide | [CI] Contraindicated withChronic kidney disease, stage 2 (mild) [CI]Chronic kidney disease, stage 2 (mild) [CI] Chronic kidney disease, stage 2 (mild) [CI] Chronic kidney disease, stage 2 (mild) [DDI] The risk or severity of renal failure and hypotension can be increased when Furosemide is combined with Losartan. | |
| Triamcinolone | [DDI] The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Furosemide. [DDI] The metabolism of Zolpidem can be increased when combined with Triamcinolone. | |
| Zolpidem | [DDI] Oxycodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. The metabolism of Zolpidem can be decreased when combined with Losartan. [DDI] Oxycodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. The metabolism of Zolpidem can be decreased when combined with Losartan. [DDI] Oxycodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. The metabolism of Zolpidem can be decreased when combined with Losartan. [DDI] Oxycodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. The metabolism of Zolpidem can be decreased when combined with Losartan. [DDI] The metabolism of Zolpidem can be decreased when combined with Losartan. | |



PATIENT DEMOGRAPHICS

| | | |
|--|--|---|
| <p>Patient Name: MARY JONES</p> <p>Lab: Newstar Medical Laboratories - Atlanta</p> | <p>[DDI] The metabolism of Oxycodone can be increased when combined with Triamcinolone. The risk of severity of hypokalemia can be increased when Triamcinolone is combined with Furosemide.</p> | <p>Accession: 2112060000</p> <p>Generated: 04/05/2022</p> |
|--|--|---|



Newstar Medical Laboratories - Atlanta
975 Cobb Place Blvd NW, STE 218 Kennesaw, GA 30144
Phone: (678) 505-8016 | Fax:(678) 806-7192

CLIA ID: 11D2145553
Laboratory Director : Chesie Voma

| | | | |
|-------------------------|--------------------------------------|--|--------------------------------------|
| PATIENT DEMOGRAPHICS | Patient Name: MARY JONES | Account: Desert Kidney Associates Casa Grande Florence | Order Code: 2021-0011992 |
| | DOB: 12/22/1951 | Provider: Ruchir Patel | Sample Type: Urine |
| | Patient Gender: F | Accession: 21120600024 | Collected: 12/02/2021 |
| | Patient Phone Number: (520) 868-4812 | Report Status: | Received: 2021-12-06T15:34:17.181050 |
| | | | Reported: 04/05/2022 |

| NOT PRESCRIBED | | | | NOT DETECTED | | | |
|------------------------|----------------|-------------------------|----------------|------------------------|----------------|------------------|----------------|
| Test | Cutoff (ng/mL) | Test | Cutoff (ng/mL) | Test | Cutoff (ng/mL) | Test | Cutoff (ng/mL) |
| Quetiapine | 50 | alpha-Hydroxyalprazolam | 30 | Dihydrocodeine | 50 | Norbuprenorphine | 30 |
| Ritalinic Acid | | Alprazolam | 30 | Diltiazem | 50 | Nordiazepam | 40 |
| Sertraline | 50 | Amitriptyline | 50 | Ethyl Sulfate | | Norfentanyl | 8 |
| Tapentadol | 50 | Amphetamine | 200 | Glipizide | 10 | Norhydrocodone | 50 |
| Temazepam | 40 | Aripiprazole | 20 | Glyburide | 10 | Norhydromorphone | |
| Topiramate | 50 | Atenolol | 50 | Haloperidol | 25 | Normeperidine | 100 |
| Pitavastatin | 10 | Atomoxetine | 50 | Hydrocodone | 50 | Norpropoxyphene | 100 |
| Pregabalin | 150 | Baclofen | 50 | Hydromorphone | 50 | Nortriptyline | 50 |
| Propoxyphene | | Buprenorphine | 10 | Hydroxybupropion | 50 | Norverapamil | 50 |
| Propranolol | 50 | Bupropion | | Ibuprofen | | Protriptyline | 50 |
| Paroxetine | 25 | Buspirone | 50 | Imipramine | 50 | Pseudoephedrine | 50 |
| Phentermine | 100 | Carbamazepine | 50 | Indomethacin | 50 | Risperidone | 10 |
| Pioglitazone | 50 | Carbamazepine Epoxide | | Irbesartan | 50 | Rivaroxaban | 50 |
| Diphenhydramine | 50 | Carboxycyclogrel | 50 | Levetiracetam | 50 | Rosuvastatin | 20 |
| Donepezil | 50 | Carisoprodol | 100 | Lisinopril | 50 | Salicylic Acid | 400 |
| Doxepin | 30 | Celecoxib | 50 | Lorazepam | 40 | Sitagliptin | 50 |
| Duloxetine | 50 | Chlorpromazine | 25 | Lurasidone | 25 | Sumatriptan | 50 |
| Ethyl Glucuronide | | Citalopram | | Meperidine | | THC-COOH | 50 |
| Fentanyl | 2 | Clonazepam | 20 | Meprobamate | 200 | Tramadol | 100 |
| Fluoxetine | 25 | Clonidine | 50 | Metformin | 500 | Trazodone | 50 |
| Gabapentin | 1000 | Clopidogrel | | Methylphenidate | | Valsartan | 50 |
| O-Desmethyltramadol | 100 | Clozapine | | Metoprolol | 50 | Venlafaxine | 100 |
| O-Desmethylvenlafaxine | 100 | Codeine | 50 | Mirtazapine | | Verapamil | |
| Olanzapine | 25 | Cotinine | 50 | Morphine | 50 | Warfarin | 10 |
| Oxazepam | 40 | Cyclobenzaprine | 50 | Naloxone | 10 | Ziprasidone | 25 |
| Hydrochlorothiazide | 50 | Dehydroaripiprazole | 20 | Naproxen | 100 | Zolmitriptan | 50 |
| 4-Hydroxydiclofenac | 50 | Desipramine | 50 | N-Desmethylcitalopram | 50 | | |
| 7-Aminoclonazepam | 40 | Diazepam | 10 | N-Desmethylclozapine | 25 | | |
| 9-Hydroxyrisperidone | 10 | Diclofenac | 50 | N-Desmethylmirtazapine | 25 | | |
| Acetaminophen | 400 | Digoxin | 10 | N-Desmethylolanzapine | 25 | | |

IMPORTANT DISCLAIMER NOTICE : Newstar warrants that all lab analysis provided is conducted professionally in accordance with all applicable standard laboratory practices and that this data reflects Newstar's attempt to generate accurate results for the specific sample(s) submitted to generate this report. Newstar has developed the tests used during the lab analysis and determined their performance characteristics. The tests have not been cleared or approved by the Food and Drug Administration. The results provided are based on information provided by the Customer. Report results are contingent on the accuracy of the prescription list, diagnosis codes, and government databases used to determine drug contraindications and drug interactions. This data reflects Newstar's attempt to generate accurate results based on the information that was provided to Newstar by the Customer and relying on the established government databases available to Newstar for the specific sample(s). Newstar disclaims any and all liability for any errors and is not responsible for any claims or damages related to the reliability of the test results.